← Leaderboards
Gonul Velicelebi
Sanford Burnham Prebys Medical Discovery Institute
$8,970,452
Attributed
$26,911,355
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10M · FY2020–25$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,911,355 · 3
By mechanism
U01$20,466,152 · 2
R01$6,445,203 · 1
Top collaborators
- Nicholas David Cosford7 shared
- Robert M Anthenelli5 shared
- Robert Warren Gould1 shared
- Benjamin S Mckenna1 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Nicholas David Cosford$46,036,569
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseDrug UsageMetabotropic Glutamate ReceptorsResearch PersonnelPropertyGlutamatesDrug KineticsInvestigational DrugsPositive Allosteric ModulatorReceptorSubstance Use DisorderRattusPharmaceutical PreparationsMultidisciplinaryAbstinenceCuesCessation Of LifeAchievementChemistryAdultAnimal ModelCigarette SmokingDesignDose
Grant awards (7)
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$2,652,771
U01 · FY2025 · DA
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$3,331,239
U01 · FY2024 · DA
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$3,064,047
U01 · FY2023 · DA
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder$6,445,203
R01 · FY2022 · DA
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$3,560,198
U01 · FY2022 · DA
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$4,154,854
U01 · FY2021 · DA
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$3,703,043
U01 · FY2020 · DA